TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02556099
Drug: Hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: drug to be administered
Study: NCT04664829
Drug: Bexarotene
Normalized name: Bexarotene
DrugBank: Bexarotene (DB00307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered orally once a day. Starting dosage: 200mg/m\^2
Study: NCT02882425
Drug: Selexipag for oral use
DrugBank: Selexipag (DB11362)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablet containing 200 µg of selexipag
Study: NCT02175342
Drug: Tiotropium 0.625 mcg/puff
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02175342
Drug: Tiotropium 1.25 mcg/puff
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02175342
Drug: Tiotropium 2.5 mcg/puff
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02175342
Drug: Tiotropium 5 mcg/puff
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02175342
Drug: Tiotropium 10 mcg/puff
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04328727
Drug: eltrombopag
Normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablet 25mg and 12.5mg
Study: NCT04328727
Drug: rabbit anti-thymocyte globulin (r-ATG)
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-ATG 25 mg sterile lyophilized powder in 10 mL vials for IV use
Study: NCT04328727
Drug: cyclosporine A (CsA)
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA 25mg Capsule or CsA 5.0g/50mL solution for oral use
Study: NCT02638116
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib will be administered at a dose of 560 milligram (mg) orally (4 x 140 mg capsules) on Day 1 and Day 7.
Study: NCT02638116
Drug: Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole will be administered at dose of 40 mg tablets orally once daily from Day 3 to Day 7.
Study: NCT03092518
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (90 mg/m\^2) will be administered via circuit to the peritoneal cavity
Study: NCT03092518
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C 10 mg/m\^2 will be administered via circuit to the peritoneal cavity
Study: NCT03092518
Drug: Sodium Thiosulfate
Normalized name: Sodium Thiosulfate
DrugBank: Thiosulfuric acid (DB09499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium thiosulfate will be administered by continuous intravenous infusion starting immediately prior to the chemotherapy perfusion and continuing for a total of 12 hours.
Study: NCT04060472
Drug: albumin-bound paclitaxel + oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Using albumin-bound paclitaxel (125 mg/m2, d1, 8, 15, ivgtt) + oxaliplatin (80 mg/m2, d1, 8, ivgtt) with or without other chemotherapeutic drugs, 28 days /cycle, until the disease progresses or patients can not tolerate toxicity. The investigators decide the follow-up treatment plan.
Study: NCT03755700
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As a gel capsule of vitamin E 800 IU orally 2 hours before intervention and 400 IU orally 4 hours after intervention
Study: NCT03755700
Drug: N-acetyl cysteine
Normalized name: N-Acetyl Cysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As an effervescent tablets of NAC 1200 mg orally 2 hours before intervention and 1200 mg orally 4 hours after intervention
Study: NCT02588131
Drug: tremelimumab plus MEDI4736
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tremelimumab1 mg/kg i.v over 60 minutes plus MEDI 4736 20 mg/kg i.v every four weeks for 4 doses, then MEDI4736 20 mg/kg IV every four weeks for additional 9 doses.
Study: NCT00529568
Drug: eltrombopag
Normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: double-blind active treatment daily oral administation at dose of 25, 50, 75, or 100 mg
Study: NCT03888105
Drug: Odronextamab
Normalized name: Odronextamab
DrugBank: Odronextamab (DB16684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by intravenous (IV) infusion
Study: NCT03600883
Drug: sotorasib
Normalized name: SOTORASIB
DrugBank: Sotorasib (DB15569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Characterize the pharmacokinetics (PK) of sotorasib following administration as an oral Tablet formulation
Study: NCT03600883
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered as an oral hydrochloride (HCI) syrup
Study: NCT00524875
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: One dose of bevacizumab (1.25 mg/0.05 cc) one to two weeks before pars plana vitrectomy for diabetic retinopathy
Study: NCT01201356
Drug: Fingolimod
Normalized name: Fingolimod
DrugBank: Fingolimod (DB08868)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 0.5 mg/day
Study: NCT00796211
Drug: CRx-197
Normalized name: CRx-119
DrugBank: CRx-119 (DB05688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRx-197 high dose topical cream (0.1% nortriptyline HCl +0.3% loratadine)
Study: NCT00796211
Drug: CRx-197
Normalized name: CRx-119
DrugBank: CRx-119 (DB05688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRx-197 low dose topical cream (0.1% nortriptyline HCl + 0.1% loratadine)
Study: NCT00796211
Drug: Nortriptyline
Normalized name: Nortriptyline
DrugBank: Nortriptyline (DB00540)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.1% nortriptyline HCl topical cream
Study: NCT00796211
Drug: Calcipotriol
Normalized name: Calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.005% calcipotriol topical cream
Study: NCT00217971
Drug: Dronabinol
Normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dronabinol
Study: NCT03476655
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: No study treatment will be administered as a part of this study. Participants in this observational study with confirmed diagnosis of CLL and MCL receiving ibrutinib treatment before 30 April 2018 in routine clinical practice settings will be observed.
Study: NCT04375384
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A loading dose of Cetuximab will be administered intravenously in the first day of treatment. The dose is 400 mg/m2 and will be infused over 2h followed by 1h observation.~The maintenance dose of Cetuximab is 250 mg/m2 and will be infused over 1h. No further observation time needed.~The maintenance dose of cetuximab will be given every 7 days (+/- 2 days) starting 7 days (+/- 2 days) after the loading dose of cetuximab.~Pre-medicate with 50 mg Diphenhydramine IV before the loading dose of Cetuximab and as per standard of care before the maintenance treatment.
Study: NCT03374085
Drug: CC-92480
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-92480
Study: NCT03374085
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone
Study: NCT04054167
Drug: Low Dose Radiation Therapy
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Undergo ultra low dose radiation
Study: NCT02809534
Drug: Anlotinib
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib p.o. qd
Study: NCT01796041
Drug: Indocyanine Green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02556632
Drug: Curcumin-based Gel
DrugBank: Cumin (DB10864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied topically
Study: NCT00936403
Drug: NNC126-0083
Normalized name: NNC126-0083
DrugBank: Somatropin pegol (DB15112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One single dose administered in four dose levels in an escalating order
Study: NCT00936403
Drug: somatropin
Normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A daily dose of Norditropin NordiFlex® for seven days. Dose will remain constant
Study: NCT00037869
Drug: I-131 Metaiodobenzylguanidine
Normalized name: iobenguane I-131
DrugBank: Guanidine (DB00536)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03182244
Drug: Gilteritinib
Normalized name: Gilteritinib
DrugBank: Gilteritinib (DB12141)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablet administered orally once daily.
Study: NCT03182244
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Once/twice daily Intravenously (IV)/subcutaneously (SC).
Study: NCT03182244
Drug: Mitoxantrone
Normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once daily IV injection.
Study: NCT03182244
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Once daily IV injection.
Study: NCT02068404
Drug: Nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03182244
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Once daily IV/SC injection.
Study: NCT03182244
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily IV injection.
Study: NCT02146378
Drug: Vyndaqel
Normalized name: Vyndaqel
DrugBank: Tafamidis (DB11644)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 20mg/day
Study: NCT00305110
Drug: 2 mg IV hydromorphone
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03036995
Drug: Apremilast
Normalized name: Apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patient will receive narrow UVB treatment and apremilast (2 tablets for day) during 24 weeks. If the patient is responder (response is defined as an increase of at least 30 % in the VASI score at W24 compare to Baseline), he will receive narrow UVB treatment according the and apremilast during 24 weeks.
Study: NCT00000512
Drug: colestipol
Normalized name: Colestipol
DrugBank: Colestipol (DB00375)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colestipol was begun at a dose of 5 g three times a day with meals and increased to 10 g three times a day after 10 days, unless side effects delayed the increase. Psyllium hydrophic mucilloid (Metamucil) was provided if dietary bran was insufficient to control constipation.
Study: NCT00000512
Drug: niacin
Normalized name: Niacin
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin was started at 125 mg twice a day and gradually increased to 500 mg four times a day (with meals and at bedtime) at one month and 1 g four times a day at two months. If the LDL cholesterol level did not fall below 3.1 mmol per liter (120 mg per deciliter) after three months, the dose of niacin was increased to 1.5 g (three tablets) four times a day, but no further.
Study: NCT00568152
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75mg dispersable aspirin taken daily for 14 days
Study: NCT01120600
Drug: Odanacatib
Normalized name: Odanacatib
DrugBank: Odanacatib (DB06670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One 50 mg tablet once weekly
Study: NCT01120600
Drug: Placebo for Odanacatib
DrugBank: Odanacatib (DB06670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One 50 mg tablet once weekly
Study: NCT01272193
Drug: insulin degludec/insulin aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Injected subcutaneously (under the skin) once daily prior to the largest meal of the day as monotherapy or combined with no more than 2 oral anti-diabetic drugs (OADs).
Study: NCT01272193
Drug: insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered according to approved labelling either as monotherapy or combined with no more than 2 OADs.
Study: NCT01222871
Drug: Triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone soaked nasopore dressing
Study: NCT03530033
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local injection of lidocaine reduces muscle tremor
Study: NCT01700751
Drug: brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03387592
Drug: Calcio levofolinate
Normalized name: Calcio
DrugBank: Calcium (DB01373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/m2
Study: NCT03387592
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m2 + 2400 mg/m2
Study: NCT03387592
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg/m2
Study: NCT02099058
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: It is administered orally everyday.
Study: NCT02099058
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: It is an intravenous infusion administered every 14 days.
Study: NCT02099058
Drug: Telisotuzumab vedotin
Normalized name: Telisotuzumab vedotin
DrugBank: Telisotuzumab vedotin (DB15104)
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is administered by infusion in 21-day dosing cycles.
Study: NCT02099058
Drug: Telisotuzumab vedotin
Normalized name: Telisotuzumab vedotin
DrugBank: Telisotuzumab vedotin (DB15104)
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is administered by infusion in 28-day dosing cycles.
Study: NCT02099058
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: It is administered orally everyday.
Study: NCT02175654
Drug: Regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01058382
Drug: Progesterone Vaginal Suppositories
Normalized name: progesterone Vaginal Insert
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone Vaginal Suppositories 200 mg three times daily for 10 weeks following embryo transfer
Study: NCT01455376
Drug: hyperosmolar sodium lactate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in this group received intravenous infusion of hyperosmolar sodium lactate at 1.5 ml.KgBW-1 within 15 minutes before neurosurgery
Study: NCT01058382
Drug: Intramuscular Progesterone-in-Oil
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone-in-Oil 50 mg IM once daily for 10 weeks following embryo transfer
Study: NCT04036227
Drug: GS-248
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GS-248 oral solution
Study: NCT00543582
Drug: MGCD0103 and Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In Part 1 of the study, up to 22 people to enroll will receive a single, oral dose (75 mg gelcap) of MGCD0103 and FB-MGCD0103 during their first 2 weeks in the study. Up to 22 additional people will receive a single dose of both MGCD0103 and TA-FB-MGCE0103. The next group of people to enroll will receive 2 different single doses (25, 50, 100 mg) of FB-MGCD0103 or TA-FB-MGCD0103 during their first 2 weeks in the study.~In Part 2 of the study, from Day 1-5 of each 28-day cycle, all subjects will receive a dose of azacitidine (75 mg/m2) either subcutaneously or through an intravenous device, and on days 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, a single, oral dose (85 mg) of MGCD0103 until progression or unacceptable toxicity develops.
Study: NCT03229382
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients, in whom all inclusion criteria have been confirmed and all exclusion criteria have been ruled out, will receive 4 intravenous infusions of obinutuzumab (GA101, Gazyvaro) at a dose of 1000 mg on Days 1, 8, 15 and 22.
Study: NCT02661282
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT00228540
Drug: Modafinil
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02194166
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab IV or SC will be administered as described.
Study: NCT02194166
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel will be administered in accordance with local hospital practice.
Study: NCT02194166
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel will be administered in accordance with local hospital practice.
Study: NCT03435640
Drug: bempegaldesleukin
Normalized name: Bempegaldesleukin
DrugBank: Bempegaldesleukin (DB15140)
Approvals — FDA: no, EMA: no, PMDA: no
Description: During Phase 1 Doublet (Cohort A), and proposed Phase 2 Doublet: Patients receive 0.006 mg/kg bempegaldesleukin administered in 3-week treatment cycles.~During Phase 1 Triplet (Cohort B), and proposed Phase 2 Triplet: Patients receive 0.006 mg/kg bempegaldesleukin administered in 3-week treatment cycles.
Study: NCT03005379
Drug: Fecal Microbiota Therapy (FMT)
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule-delivered FMT
Study: NCT03435640
Drug: nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: During Phase 1 Triplet (Cohort B), and proposed Phase 2 Triplet: Patients receive a nivolumab flat dose of 360 mg administered in 3-week treatment cycles.
Study: NCT02165566
Drug: Lispro-insulin
Normalized name: insulin lispro-insulin lispro protamine
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patients are assigned in a random sequence to receive Regular-insulin or lispro-insulin infusion
Study: NCT04221087
Drug: Dexamethasone Oral
Normalized name: dexamethasone Oral Tablet
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.6mg/kg/dose - single oral dose administration to intervention arm
Study: NCT05222243
Drug: Direct pulp capping with Formocresol
Normalized name: acai fruit pulp
DrugBank: Cresol (DB11143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capping exposed dental pulps during cavity preparation in primary teeth with zinc oxide eugenol after medication with formocresol
Study: NCT01022502
Drug: refined indigo naturalis ointment
Normalized name: indigo
DrugBank: Indigo (DB16862)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients applied either refined oil extract or crude indigo naturalis ointmnet topically to each of two bilaterally symmetrical psoriatic plaque lesions for 8 weeks.
Study: NCT01022502
Drug: crude indigo naturalis ointment
Normalized name: indigo
DrugBank: Indigo (DB16862)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients applied either refined oil extract or crude indigo naturalis ointmnet topically to each of two bilaterally symmetrical psoriatic plaque lesions for 8 weeks.
Study: NCT03716050
Drug: Nitroglycerin
Normalized name: Nitroglycerin
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient's will be randomized into one of eight groups and receive the intended treatment specified for that particular group. Groups 2,4,6, and 8 will include Nitroglycerin cream.
Study: NCT01500551
Drug: Tofacitinib
Normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tofacitinib will be administered orally BID (twice daily) approximately 12 hours (±2 hours) apart, once in the morning and once in the evening, based on body weight for all subjects for all three index studies (A3921103, A3921104, and A3921165)~5 mg BID Dose Level:~Body Weight (Dose in tablet \[mg BID\] or solution \[ml BID\]) 5 - \< 7 kg (2 mg or 2 ml) 7 - \< 10 kg (2.5 mg or 2.5 ml) 10 - \<15 kg (3 mg or 3 ml) 15 - \<25 kg (3.5 mg or 3.5 ml) 25 - \<40 kg (4 mg or 4 ml) \>=40 kg (5 mg or 5 ml)~Oral solution (1 mg/mL concentration) will be used for subjects weighing \<40 kg. Oral tablets (5 mg) will be used for subjects weighing \>=40 kg; subjects who are unable to swallow tablets will have the option of taking oral solution.~Subjects will swallow study tablets whole and will not manipulate or chew tablets prior to swallowing.
Study: NCT01500551
Drug: Tofacitinib
Normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: For subjects rolling over from study A3921103 and actively participating in this study at the time of Protocol Amendment 6 and receiving a dosage of tofacitinib in accordance with the dosing scheme specified in Protocol Amendment 5, investigators will have the option of maintaining the subject's current dosage regimen from index study A3921103 (if the desired clinical response has been attained with no safety concern) or adjusting the dosage regimen in accordance with the dosing scheme specified in this section.
Study: NCT01479842
Drug: BTK inhibitor PCI-32765
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01479842
Drug: bendamustine hydrochloride
Normalized name: Bendamustine Hydrochloride
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01935869
Drug: Petrolatum ointment
Normalized name: GERI PROTECT Petrolatum Ointment
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06215521
Drug: Pirtobrutinib
Normalized name: Pirtobrutinib
DrugBank: Pirtobrutinib (DB17472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT06215521
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01829568
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO